| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 9.3 | 6.4 | 8.9 |
| Other income | 0.4 | 0.0 | 0.0 |
| Total income | 9.7 | 6.4 | 9.0 |
| Profit before exceptional items & tax | 0.2 | -0.3 | 0.1 |
| Profit before tax | 0.2 | -0.3 | 0.1 |
| Net profit | 0.1 | -0.5 | 0.1 |
| Operating margin | 2.1% | -4.7% | 1.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Revenue, year on year | +4.50% |
| Operating profit, year on year | -300.00% |
| Operating profit, quarter on quarter | +33.30% |
Source
Read the filing ↗
BSE results filing, NSE: VIVANZA. Figures extracted from the filing.
Vivanza Biosciences Ltd: key numbers
- Share price
- ₹1.77
- Market cap
- ₹7.08 Cr
- Revenue (annual)
- ₹115.9 Cr
- Net profit (annual)
- ₹0.39 Cr
- P/E (TTM)
- 15.6×Sector 50.4×
- Promoter holding
- 20.02%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivanza Biosciences Ltd
All →
12:13 IST
BSE
Annual General Meeting
Vivanza Biosciences Annual General Meeting
Vivanza Biosciences has convened its 44th AGM on September 11, 2026 via VC/OAVM. Nine agenda items cover financial statements, director appointments, and borrowing limit approvals.
22:58 IST
BSE
Financial Results
Vivanza Biosciences Q4 FY26 Results: Net Loss of ₹0.5 Cr, Loss Narrows
Vivanza Biosciences Ltd reported revenue from operations of ₹6.4 Cr (+1180.0% YoY) and a net loss of ₹0.5 Cr for Q4 FY26.
- Key figure
- Net loss ₹0.5 Cr